Cargando…

Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer

Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in PCa is unknown. Two cohorts of patients with PCa who underwent radical prostatectomy (n = 40, n = 56) and benign prosta...

Descripción completa

Detalles Bibliográficos
Autores principales: Waldbillig, Frank, Nitschke, Katja, Abdelhadi, Abdallah, von Hardenberg, Jost, Nuhn, Philipp, Nientiedt, Malin, Weis, Cleo-Aron, Michel, Maurice Stephan, Erben, Philipp, Worst, Thomas Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352472/
https://www.ncbi.nlm.nih.gov/pubmed/32575490
http://dx.doi.org/10.3390/ijms21124373
_version_ 1783557646052229120
author Waldbillig, Frank
Nitschke, Katja
Abdelhadi, Abdallah
von Hardenberg, Jost
Nuhn, Philipp
Nientiedt, Malin
Weis, Cleo-Aron
Michel, Maurice Stephan
Erben, Philipp
Worst, Thomas Stefan
author_facet Waldbillig, Frank
Nitschke, Katja
Abdelhadi, Abdallah
von Hardenberg, Jost
Nuhn, Philipp
Nientiedt, Malin
Weis, Cleo-Aron
Michel, Maurice Stephan
Erben, Philipp
Worst, Thomas Stefan
author_sort Waldbillig, Frank
collection PubMed
description Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in PCa is unknown. Two cohorts of patients with PCa who underwent radical prostatectomy (n = 40, n = 56) and benign prostate hyperplasia (BPH) controls (n = 8, n = 11) were profiled for SMPDL3B expression with qRT-PCR. Publicly available PCa cohorts (Memorial Sloane Kettering Cancer Centre (MSKCC; n = 131, n = 29 controls) and The Cancer Genome Atlas (TCGA; n = 497, n = 53 controls)) served for validation. SMPDL3B’s impact on proliferation and migration was analyzed in PC3 cells by siRNA knockdown. In both cohorts, a Gleason score and T stage independent significant overexpression of SMPDL3B was seen in PCa compared to BPH (p < 0.001 each). A lower expression of SMPDL3B was associated with a shorter overall survival (OS) (p = 0.005) in long term follow-up. A SMPDL3B overexpression in PCa tissue was confirmed in the validation cohorts (p < 0.001 each). In the TCGA patients with low SMPDL3B expression, biochemical recurrence-free survival (p = 0.011) and progression-free interval (p < 0.001) were shorter. Knockdown of SMPDL3B impaired PC3 cell migration but not proliferation (p = 0.0081). In summary, SMPLD3B is highly overexpressed in PCa tissue, is inversely associated with localized PCa prognosis, and impairs PCa cell migration.
format Online
Article
Text
id pubmed-7352472
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73524722020-07-15 Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer Waldbillig, Frank Nitschke, Katja Abdelhadi, Abdallah von Hardenberg, Jost Nuhn, Philipp Nientiedt, Malin Weis, Cleo-Aron Michel, Maurice Stephan Erben, Philipp Worst, Thomas Stefan Int J Mol Sci Article Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in PCa is unknown. Two cohorts of patients with PCa who underwent radical prostatectomy (n = 40, n = 56) and benign prostate hyperplasia (BPH) controls (n = 8, n = 11) were profiled for SMPDL3B expression with qRT-PCR. Publicly available PCa cohorts (Memorial Sloane Kettering Cancer Centre (MSKCC; n = 131, n = 29 controls) and The Cancer Genome Atlas (TCGA; n = 497, n = 53 controls)) served for validation. SMPDL3B’s impact on proliferation and migration was analyzed in PC3 cells by siRNA knockdown. In both cohorts, a Gleason score and T stage independent significant overexpression of SMPDL3B was seen in PCa compared to BPH (p < 0.001 each). A lower expression of SMPDL3B was associated with a shorter overall survival (OS) (p = 0.005) in long term follow-up. A SMPDL3B overexpression in PCa tissue was confirmed in the validation cohorts (p < 0.001 each). In the TCGA patients with low SMPDL3B expression, biochemical recurrence-free survival (p = 0.011) and progression-free interval (p < 0.001) were shorter. Knockdown of SMPDL3B impaired PC3 cell migration but not proliferation (p = 0.0081). In summary, SMPLD3B is highly overexpressed in PCa tissue, is inversely associated with localized PCa prognosis, and impairs PCa cell migration. MDPI 2020-06-19 /pmc/articles/PMC7352472/ /pubmed/32575490 http://dx.doi.org/10.3390/ijms21124373 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Waldbillig, Frank
Nitschke, Katja
Abdelhadi, Abdallah
von Hardenberg, Jost
Nuhn, Philipp
Nientiedt, Malin
Weis, Cleo-Aron
Michel, Maurice Stephan
Erben, Philipp
Worst, Thomas Stefan
Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
title Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
title_full Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
title_fullStr Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
title_full_unstemmed Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
title_short Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
title_sort phosphodiesterase smpdl3b gene expression as independent outcome prediction marker in localized prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352472/
https://www.ncbi.nlm.nih.gov/pubmed/32575490
http://dx.doi.org/10.3390/ijms21124373
work_keys_str_mv AT waldbilligfrank phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT nitschkekatja phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT abdelhadiabdallah phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT vonhardenbergjost phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT nuhnphilipp phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT nientiedtmalin phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT weiscleoaron phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT michelmauricestephan phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT erbenphilipp phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer
AT worstthomasstefan phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer